Hutchmed (China) Limited 2021 Annual Report and Notice of AGM (6499F)

TIDMHCM

RNS Number : 6499F

Hutchmed (China) Limited

23 March 2022

2021 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai, & Florham Park, NJ - Wednesday, March 23, 2022: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; HKEX:13) today announces that its 2021 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials") will be posted to shareholders on March 24, 2022 who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website ( www.hutch-med.com ).

The 2022 Annual General Meeting ("AGM") will be held at the Conference Room, 18(th) Floor, Hutchison Telecom Tower, 99 Cheung Fai Road, Tsing Yi, Hong Kong on Wednesday, April 27, 2022 at 6:00 pm Hong Kong Time (11:00 am London Time).

To safeguard the health and safety of shareholders, HUTCHMED encourages shareholders to: (i) attend the AGM online and vote by means of electronic facilities; or (ii) exercise their right to vote at the AGM by appointing the Chairman of the AGM as their proxy. Shareholders will be able to view a live webcast of the AGM through the website of the Company at www.hutch-med.com/event/ . All registered shareholders will also receive a letter containing log in details and information on how to access the webcast.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,600 personnel across all its companies, at the center of which is a team of about 1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

 
Investor Enquiries 
   Mark Lee, Senior Vice President        +852 2121 8200 
   Annie Cheng, Vice President            +1 (973) 567 3786 
Media Enquiries 
   Americas - Brad Miles,                 +1 (917) 570 7340 (Mobile) 
    Solebury Trout                         bmiles@troutgroup.com 
   Europe - Ben Atwell / Alex Shaw,       +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) 
    FTI Consulting                         HUTCHMED@fticonsulting.com 
   Asia - Zhou Yi,                        +852 9783 6894 (Mobile) 
    Brunswick                              HUTCHMED@brunswickgroup.com 
Nominated Advisor 
   Atholl Tweedie / Freddy Crossley, 
    Panmure Gordon (UK) Limited           +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFLFFEVVIFFIF

(END) Dow Jones Newswires

March 23, 2022 04:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024